A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis
NCT ID: NCT00851500
Last Updated: 2011-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
210 participants
INTERVENTIONAL
2009-02-28
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque
NCT07050134
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
NCT00995930
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
NCT03248401
Evaluation of Cilostazol in Combination With L-Carnitine
NCT00822172
Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease
NCT06342609
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
low dose K-604
K-604
K-604 is given for 26 weeks
high dose K-604
K-604
K-604 is given for 26 weeks
placebo
Placebo
placebo tablets are given for 26 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
K-604
K-604 is given for 26 weeks
Placebo
placebo tablets are given for 26 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* heavily calcified plaque
* uncontrolled hypertension
* poorly controlled diabetes
* hypercholesterolemia
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kowa Research Institute, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kowa Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chandler, Arizona, United States
Litchfield Park, Arizona, United States
Phoenix, Arizona, United States
Los Angeles, California, United States
San Diego, California, United States
Clearwater, Florida, United States
Jacksonville, Florida, United States
St Louis, Missouri, United States
Buffalo, New York, United States
Oklahoma City, Oklahoma, United States
Carrollton, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Plano, Texas, United States
Norfolk, Virginia, United States
Virginia Beach, Virginia, United States
Olympia, Washington, United States
Renton, Washington, United States
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
K-604-2.01US
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.